Researchers we empower:
Empowering Academic Research
We accuratly identify and sift out toxic compounds for the human kidney during pre-clinical stages of drug development. By using our highly accurate and stable human renal ciPTEC cell line.
Highly accurate renal toxicity research
The functional drug transporters and endocytic apparatus lead to a realistic cellular response to toxicant exposures. Our experts in the field of pharmacology and toxicology can support you to elucidate the underlying mechanism of renal adverse effects observed in your lead compounds by developing cell-based assays based on our ciPTEC technology.
Easy to use following standard culturing protocols
Cell4Pharma’s ciPTEC can be cultured using standard culturing protocols that we provide to you. Cell4Pharma’s ciPTEC models are used in 30+ laboratories world-wide and used in 60+ peer-reviewed scientific publications. This clearly demonstrates that our protocols and cell-based assays can be transferred and implemented at your facility.
Extensive validated research
ciPTEC is the basis for a range of cell-based assays More than 10 years of research and collaborations research consortia have led to a range of cell-based assays based on ciPTEC. Next to drug interaction studies, IC50 determinations, toxicity studies, gene expression analysis, miRNA biomarker screenings, ciPTEC allows the detection of specific biomarkers upon toxicant exposures and have elucidated several mechanisms of disease.
Unlimited proliferation capacity
Create your own stock and ciPTEC is available to you throughout your entire research career. Cell4Pharma’s ciPTEC technology is based on a human renal cell line with unlimited proliferation capacity. Our cells have stable drug transport functionality for at least 20 passages. When creating your own stock, this means your assay will provide the same data, over and over again.
Empowering Academic Research
We accuratly identify and sift out toxic compounds for the human kidney during pre-clinical stages of drug development. By using our highly accurate and stable human renal ciPTEC cell line.
Highly accurate renal toxicity research
The functional drug transporters and endocytic apparatus lead to a realistic cellular response to toxicant exposures. Our experts in the field of pharmacology and toxicology can support you to elucidate the underlying mechanism of renal adverse effects observed in your lead compounds by developing cell-based assays based on our ciPTEC technology.
Easy to use following standard culturing protocols
Cell4Pharma’s ciPTEC can be cultured using standard culturing protocols that we provide to you. Cell4Pharma’s ciPTEC models are used in 30+ laboratories world-wide and used in 60+ peer-reviewed scientific publications. This clearly demonstrates that our protocols and cell-based assays can be transferred and implemented at your facility.
Extensive validated research
ciPTEC is the basis for a range of cell-based assays More than 10 years of research and collaborations research consortia have led to a range of cell-based assays based on ciPTEC. Next to drug interaction studies, IC50 determinations, toxicity studies, gene expression analysis, miRNA biomarker screenings, ciPTEC allows the detection of specific biomarkers upon toxicant exposures and have elucidated several mechanisms of disease.
Unlimited proliferation capacity
Create your own stock and ciPTEC is available to you throughout your entire research career. Cell4Pharma’s ciPTEC technology is based on a human renal cell line with unlimited proliferation capacity. Our cells have stable drug transport functionality for at least 20 passages. When creating your own stock, this means your assay will provide the same data, over and over again.
Highly accurate and stable human renal ciPTEC Cell Lines Characteristics
Robust data
The stable transfection and maintained epithelial characteristics lead to a cell line that will produce very robust data. Our validation studies demonstrated robust data for more than 20 passages.
Transferable between laboratories
Our ciPTEC technology is a result of more than 10 years of research in world-wide collaborations. We have successfully transferred our protocols to collaborating laboratories.
Intact drug transporter functionality
Using fluorescent probes specific for a transporter, we could demonstrate the functional expression of OCT2, P-glycoprotein, MRP4, BCRP and OAT1 (in ciPTEC-OAT1) and OAT3 (in ciPTEC-OAT3). The transport of fluorescent probes could be inhibited using specific inhibitors or competitors.
Unlimited proliferation from cryo stocks
Just as any cell line, ciPTEC can be stored in liquid nitrogen to create your own stock. Upon thawing, ciPTEC will proliferate at 33°C and maintain it’s characteristics.
Proximal tubular epithelial characteristics
Extensive characterization demonstrated that ciPTEC in culture keeps its proximal tubular epithelial characteristics, such as specific transporter expression (OCT2, P-glycoprotein, MRP4, BCRP, NaPi2), gamma-glutamyl transferase expression, ZO-1 and CD13 expression, as well as the formation of cilia.
Conditionally immortalized
By viral transfection using SV40t antigen and hTERT, ciPTEC is proliferating at 33°C, while the SV40t antigen is absent upon culturing at 37°C, where ciPTEC proliferation is reduced.
Relevant drug transporter expression
Following characterization on a protein and gene level, we demonstrated specific transporter expression (OCT2, P-glycoprotein, MRP4, BCRP) in ciPTEC. Following stable transfection using vectors containing the human OAT1 and OAT3, we created ciPTEC-OAT1 and ciPTEC-OAT3 models.
Human origin
ciPTEC was originally derived from a human donor (female). The human origin results in the high predictivity for human renal adverse events and the versatile use of ciPTEC in the fields of pharmacology, nephrology, physiology and human pathology.
Used in 60+ peer-reviewed scientific publication
More than 10 years of research in world-wide academic and industry collaborations have lead to 60+ peer-reviewed scientific publications in the fields of pharmacology, nephrology, physiology and human pathology.
Industry Benefits
Low inter-laboratory
variations
Compatible with high-throughput screening equipment
Produce data with high reproducibility
Expression of specific biomarkers for renal toxicity upon toxicant exposure
Reduction of animal experiments upon full validation
Applicable in Organ-on-a-Chip devices to mimic 3D tubular structures
Join C4P Academic
Partner Program:
Align our strengths to further the research on renal toxicity. Contact us to discuss partnership opportunities.
World Wide Renal Tox Network
– Our network spans to over 30 universities.
– Our models are used in over 30+ laboratories world-wide and used in over 60+ peer-reviewed scientific publications.
Updates
– We share the latest updates on the development surrounding ciPTEC and renal toxicity research.
Support
– We provide support with your research and publications.
Assays
– Access to our constantly growing library of assays and publications.
Testimonials
Because the cell line is robust in culture, the research leads to reliable results. As far as I am concerned, there is currently no kidney epithelial cell line available with an equally good predictive value for the human kidney.
The ciPTEC mimics primary renal cells, but you can culture them for a long time without losing their properties. The expression of transporters gives a more accurate response to drugs and toxins. The cells grow fast and are easy to handle.
ciPTEC is a well-accepted in vitro model to screen compounds for their DIKI potential.